Tocagen Revenue and Competitors

Location

$168.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Tocagen's estimated annual revenue is currently $18M per year.(i)
  • Tocagen received $34.5M in venture funding in December 2018.
  • 0
  • Tocagen's total funding is $168.6M.

Employee Data

    00
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

We are driven by a vision to end cancer mortality. Our company was founded on this vision in 2007. Tocagen's mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. Our broadly applicable product candidates are designed to activate a patient's immune system against their cancer from within. At the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. In other words, our technology is designed to combat cancer with fewer side effects, keeping patients healthy tissue intact while the tumor is destroyed. We believe Tocagen's approach to fighting cancer using RRVs is an important scientific advancement over prior gene therapy approaches, as well as a potential complement to existing therapies. We believe our innovations may fulfill the promise of gene therapy as a safe and effective treatment for cancer. Ultimately, Tocagen exists for the patients, powered by a mission to revolutionize cancer treatment. With the right therapeutic approach, our hope is that even the most aggressive forms of cancer can be safely and effectively controlled, and each day we strive to turn that bold vision into reality.

keywords:Biotechnology,Healthcare,Human Resources Hr,Pharmaceuticals

$168.6M

Total Funding

N/A

Number of Employees

$18M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Tocagen News

2022-04-19 - Anaplastic Astrocytoma Drug Market Innovative Strategy by ...

... Novartis AG, Orbus Therapeutics Inc, Pfizer Inc, Tocagen Inc, Tragara Pharmaceuticals Inc, TVAX Biomedical Inc, ZIOPHARM Oncology Inc.

2022-03-22 - What Is Glioblastoma? Aggressive Cancer Linked to Death of Tom Parker

Though Newsweek reported in 2017 that an experimental drug developed by Tocagen had been showing promising results, MedCity News reported...

2020-02-20 - Tocagen, Forte Biosciences In Merger

San Diego-based Tocagen, which develops cancer-selective gene therapy aimted at treatking skin cancer, and Torrance-based Forte Biosciences, a biopharmaceuticals firm developing a live biotherapeutic for the treatment of inflammatory skin diseases, said on Wednesday that the two are in an agreem ...

2019-12-24 - Why is glioblastoma such a tough nut to crack?

The latest letdowns came in just the last few months. In September, San Diego-based Tocagen announced that its Phase III study of the gene therapy and prodrug combination Toca 511 and Toca FC in recurrent GBM had failed to show an improvement in overall survival, and in fact showed that patients ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.4M0N/AN/A
#2
$11.7M0N/A$4.4M
#3
$36.4M0N/A$778M
#4
$1.7M0N/AN/A
#5
$18.3M0N/A$79M

Tocagen Funding

DateAmountRoundLead InvestorsReference
2014-07-14$8.5MUndisclosedArticle
2015-08-12$28.8MUndisclosedArticle
2018-12-13$34.5MUndisclosedCitigroupArticle